Childhood Polyarteritis Nodusa

Overview

Definition

Childhood Polyarteritis Nodosa (c-PAN) is a rare, necrotizing vasculitis primarily affecting medium-sized arteries, although small arteries and arterioles can also be involved. It is characterized by segmental transmural inflammation and fibrinoid necrosis of arterial walls, leading to aneurysm formation, thrombosis, infarction, and hemorrhage in various organ systems. Unlike adult PAN, c-PAN can be associated with cutaneous manifestations more frequently (cutaneous PAN), and systemic involvement varies.

Epidemiology

c-PAN is exceedingly rare, with an estimated incidence of 1-4 per million children per year globally. It typically affects children between infancy and adolescence, with a peak incidence observed in early childhood (around 4-9 years). There is a slight male predominance, with a male-to-female ratio of approximately 1.5:1. Geographic variation in incidence is not well-established, but cases have been reported worldwide. There is a recognized association with hepatitis B virus (HBV) infection in adult PAN, but this association is less common in c-PAN, with other infections such as parvovirus B19, streptococcal infections, and cytomegalovirus being more frequently implicated in some cases.

Classification

c-PAN is broadly classified based on its extent of involvement: * Systemic c-PAN: Involves multiple organ systems with significant internal organ damage (e.g., renal, gastrointestinal, cardiac, neurological). This is the classical presentation similar to adult PAN. * Cutaneous c-PAN (c-CPAN): Predominantly affects the skin, subcutaneous tissues, and often peripheral nerves. Systemic involvement is absent or mild and limited. It generally has a more benign course but can be chronic and relapsing. Historically, some clinicians have considered c-CPAN a distinct entity, but it is now largely viewed as a localized form of PAN.

Pathophysiology

Mechanism

The exact pathophysiology of c-PAN remains largely unknown, but it is believed to involve a complex interplay of genetic predisposition, environmental triggers (especially infections), and aberrant immune responses. The central mechanism involves immune-mediated injury to the arterial walls: 1. Immune Complex Deposition: While less definitive than in other vasculitides, some theories suggest circulating immune complexes deposit in arterial walls, activating complement and initiating inflammation. 2. Neutrophil Infiltration: Activated neutrophils are prominent in early lesions, releasing lysosomal enzymes and reactive oxygen species, leading to damage of endothelial cells and smooth muscle. 3. Endothelial Dysfunction: Inflammation leads to endothelial cell activation, increased permeability, and expression of adhesion molecules, promoting further immune cell recruitment. 4. Transmural Inflammation: Inflammatory cells (neutrophils, lymphocytes, macrophages) infiltrate all layers of the arterial wall (intima, media, adventitia). 5. Fibrinoid Necrosis: Destruction of smooth muscle cells and elastic lamina in the media, leading to fibrin deposition and arterial wall necrosis. 6. Aneurysm Formation: Weakening of the arterial wall due to inflammation and necrosis can lead to microaneurysms, particularly at bifurcations. 7. Thrombosis and Occlusion: Endothelial damage, inflammation, and stasis within aneurysms promote thrombus formation, leading to arterial occlusion and subsequent ischemia and infarction of downstream tissues. 8. Fibrosis and Scarring: Healing of lesions results in fibrosis, arterial narrowing, and nodule formation along the vessel.

Risk Factors

• Infections:
  • Hepatitis B Virus (HBV): Strong association in adult PAN (especially endemic areas); less common but reported in c-PAN. HBsAg-positive c-PAN warrants specific antiviral therapy.
  • Streptococcal infections: Post-streptococcal events, particularly pharyngitis, have been implicated in a subset of c-PAN, possibly via molecular mimicry.
  • Parvovirus B19: Association suggested in some cases.
  • Cytomegalovirus (CMV), Epstein-Barr Virus (EBV): Less clear associations.
• Genetic Susceptibility: While no single gene has been definitively identified, an underlying genetic predisposition is suspected, as is common in autoimmune diseases.
• Immunizations: Temporal associations with immunizations have been reported in rare cases but are not considered directly causative.

Protective Factors

No established protective factors exist for c-PAN. Early diagnosis and aggressive, appropriate treatment are essential to mitigate disease progression and prevent severe complications.

Clinical Presentation

Signs and Symptoms

Clinical presentation is highly variable and depends on the organs and vascular beds involved.

Cardinal Features

• Fever of unknown origin: Persistent, often spiking fever is common, especially in systemic c-PAN.
• Systemic symptoms: Weight loss, fatigue, malaise, anorexia.
• Musculoskeletal pain: Arthralgia, myalgia (due to muscle ischemia).
• Cutaneous lesions: Livedo reticularis, subcutaneous nodules, purpura, ulcers, digital gangrene. These can be the sole manifestation in c-CPAN.
• Neurological symptoms: Peripheral neuropathy (mononeuritis multiplex is classic), central nervous system (CNS) involvement (seizures, stroke, headaches) due to cerebral vasculitis.
• Hypertension: Often severe and rapidly progressive, due to renal artery involvement/ischemia.
• Abdominal pain: Diffuse or localized, often postprandial, indicative of mesenteric ischemia, pancreatitis, or cholecystitis.

Early Signs

• Persistent fever without an identifiable source.
• Unexplained arthralgia or myalgia.
• New-onset or worsening hypertension.
• Cutaneous findings such as livedo reticularis or tender subcutaneous nodules.
• Changes in appetite, weight loss.

Advanced Signs

• Renal failure: Due to arterial occlusion and infarcts.
• Gastrointestinal perforation/infarction: Severe abdominal pain, peritonitis, bleeding.
• Myocardial infarction/Heart failure: Due to coronary arteritis.
• Stroke/Intracranial hemorrhage: Severe neurological deficits.
• Digital gangrene: Ischemia leading to tissue loss in extremities.

Atypical Presentations

• Isolated central nervous system vasculitis.
• Isolated coronary artery vasculitis mimicking Kawasaki disease (though PAN typically lacks the stereotypical mucosal and lymph node changes of KD).
• Localized forms presenting as a single organ system involvement, making diagnosis challenging.

Physical Examination

Inspection

• Skin: Livedo reticularis (mottled, purplish discoloration, especially on extremities), erythematous or violaceous tender subcutaneous nodules (often along blood vessels), purpura, ulcers, digital infarcts/gangrene.
• General: Pallor (anemia), signs of weight loss, distress.
• Conjunctiva/Mucosa: While not typical, pallor if anemic.

Palpation

• Abdomen: Tenderness, guarding (peritonitis), palpable masses (rare, might indicate visceral infarcts).
• Musculoskeletal: Tender muscles, joint tenderness, swelling.
• Peripheral pulses: May be diminished or absent in affected limbs, bruits over stenotic arteries.
• Subcutaneous nodules: Firm, tender nodules.

Special Tests

• Neurological examination: Assess for mononeuritis multiplex (e.g., foot drop, wrist drop), cranial neuropathies, signs of CNS involvement (e.g., altered mental status, focal deficits).
• Blood pressure measurement: Crucial for detecting hypertension; may be severe.
• Cardiac auscultation: Murmurs if valvular damage, signs of heart failure.

Diagnostic Approach

History Taking

Key Questions

• Onset and duration of symptoms: Acute vs. insidious, progression.
• Systemic symptoms: Fever, weight loss, fatigue, malaise, anorexia.
• Specific organ system review:
  • Skin: Rashes, nodules, ulcers, color changes (livedo reticularis).
  • Musculoskeletal: Joint pain, muscle pain, weakness.
  • Neurological: Numbness, tingling, weakness, seizures, headaches, vision changes.
  • Gastrointestinal: Abdominal pain (onset, character, radiation), nausea, vomiting, diarrhea, melena, hematochezia.
  • Renal: Changes in urine output, color, swelling, history of hypertension.
  • Cardiac: Chest pain, palpitations, shortness of breath.
• Infection history: Recent streptococcal infection (sore throat), viral illnesses (HBV exposure/vaccination, parvovirus, CMV, EBV).
• Medication history: Any new medications or illicit drug use (recreational PAN is rare in children).
• Family history: Autoimmune diseases, vasculitis.

Red Flags

• Unexplained persistent fever with systemic symptoms.
• New-onset severe hypertension in a child.
• Severe abdominal pain with evidence of ischemia/bleeding.
• Rapidly progressive neurological deficits or seizures.
• Digital gangrene or severe ischemic lesions of the skin/extremities.
• Evidence of multi-organ involvement (e.g., renal impairment, GI bleeding, neurological deficits).

Laboratory Tests

First-Line

• Complete Blood Count (CBC): Anemia (anemia of chronic disease, GI bleeding), leukocytosis (due to inflammation), thrombocytosis (acute phase reactant).
• Erythrocyte Sedimentation Rate (ESR) & C-Reactive Protein (CRP): Markedly elevated in active disease, serving as general markers of inflammation.
• Liver Function Tests (LFTs): May be elevated with hepatic involvement or severe systemic illness; important for HBV screening.
• Renal Function Tests (RFTs): Urea, creatinine, electrolytes. Elevated creatinine suggests renal involvement.
• Urinalysis: Hematuria, proteinuria, cellular casts, indicating glomerulonephritis or renal infarcts.
• Hepatitis B Serology: HBsAg, anti-HBs, HBeAg, anti-HBe, HBV DNA. Crucial to rule out HBV-associated PAN.
• Antistreptolysin O (ASO) titer: To assess for recent streptococcal infection, especially if suspected.
• Blood cultures: To rule out sepsis, especially with fever.
• Autoantibodies:
  • Antineutrophil Cytoplasmic Antibodies (ANCAs): Typically negative in c-PAN (distinguishes from ANCA-associated vasculitis).
  • Antinuclear Antibodies (ANA), Rheumatoid Factor (RF): Generally negative but tested to rule out other connective tissue diseases.
  • Complement levels (C3, C4): Usually normal or elevated (acute phase reactants); rarely low if significant immune complex consumption.

Confirmatory

• Tissue Biopsy:
  • Gold Standard: Biopsy of an affected organ (e.g., skin, muscle, nerve, kidney, bowel) demonstrating necrotizing vasculitis of medium-sized arteries. Findings include transmural inflammation, fibrinoid necrosis, and disruption of the internal elastic lamina. Positive biopsy is definitive.
  • Skin biopsy: If cutaneous lesions are present; often diagnostic for c-CPAN.
  • Sural nerve biopsy: If mononeuritis multiplex is present.
  • Muscle biopsy: If myalgia and muscle weakness are prominent.
  • Renal/GI biopsy: If these organs are involved and biopsy deemed safe.

Monitoring

• ESR, CRP: To monitor disease activity and response to treatment.
• CBC, RFTs, LFTs: To assess end-organ function and medication toxicity.
• Urinalysis: For ongoing renal assessment.
• Blood pressure monitoring: Crucial for management of hypertension.
• HBV DNA load: If HBV-associated PAN.

Imaging

Recommended

• Angiography (Conventional or CT/MR Angiography): The imaging modality of choice to visualize characteristic arterial lesions.
  • Mesenteric angiography: If gastrointestinal symptoms are prominent.
  • Renal angiography: If hypertension or renal involvement.
  • Coronary angiography: If cardiac symptoms or suspicion of coronary arteritis.
  • Findings: Multiple microaneurysms, fusiform dilatations, stenoses, occlusions, and irregular arterial narrowing, particularly in kidneys, mesenteric arteries, liver, and pancreas. "Beaded" appearance (alternating stenoses and aneurysms) is characteristic.
• Echocardiography: To assess for cardiac involvement (e.g., coronary aneurysms, ventricular dysfunction, pericardial effusion).
• Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scans:
  • Abdominal CT/MRI: To evaluate for bowel ischemia, infarcts, organomegaly, or hemorrhage.
  • Brain CT/MRI: If neurological symptoms (stroke, hemorrhage, infarcts).
  • CT chest: Rare, but can show pulmonary infarcts or hemorrhages if lung involvement.

Advanced

• Arteriography (Contrast angiography): Still considered the gold standard for visualizing vasculitic changes in medium-sized vessels, especially if CT/MR angiography is inconclusive or detailed vessel mapping is required pre-surgically.
• Positron Emission Tomography (PET) scan: Emerging role in detecting active inflammation in large and medium vessels, potentially guiding biopsy sites or assessing disease extent, though not yet standard in c-PAN.
• Ultrasonography with Doppler: Can be useful for evaluating organ perfusion, detecting visceral aneurysms, or assessing peripheral vascular flow, particularly in cutaneous PAN.

Management

Acute Management

Immediate

• Secure airway, breathing, circulation (ABCs): In cases of severe hemorrhage, stroke, or multi-organ failure.
• High-dose corticosteroid bolus: Immediately initiated upon suspicion of systemic c-PAN to suppress inflammation rapidly (e.g., methylprednisolone 15-30 mg/kg/day IV, max 1 gram, for 3-5 days).
• Analgesia: For severe pain (e.g., abdominal, musculoskeletal).
• Antihypertensives: For severe hypertension (e.g., labetalol, nicardipine, clevidipine IV infusion) to prevent end-organ damage.

Stabilization

• Fluid and electrolyte management: Correct fluid deficits/excesses and electrolyte imbalances.
• Nutritional support: Parenteral or enteral feeding if gut is compromised.
• Infection control: Broad-spectrum antibiotics if secondary infection is suspected, close monitoring for opportunistic infections due to immunosuppression.
• Specific organ support:
  • Renal: Dialysis if severe renal failure.
  • Gastrointestinal: Surgical consultation for perforation, hemorrhage, or severe ischemia.
  • Neurological: Anticonvulsants for seizures, neurosurgical consultation for intracranial hemorrhage.
• Anticoagulation: Consider for thrombotic events or large aneurysms, in consultation with hematology.

Emergency

• Surgical intervention: For life-threatening complications such as bowel perforation, uncontrolled hemorrhage, or impending rupture of large aneurysms.
• Plasmapheresis: Considered in severe, rapidly progressive disease, especially if unresponsive to corticosteroids and cyclophosphamide, or if associated with severe immune complex disease (rare in c-PAN).

Chronic Management

Pharmacological

• Corticosteroids:
  • Initial: Prednisone 1-2 mg/kg/day orally (maximum 60 mg/day) following IV pulse.
  • Taper: Slowly tapered over several months (6-12 months or longer) based on clinical response and inflammatory markers. Relapses often occur during taper.

• Immunosuppressive Agents (Disease-Modifying):

  • Cyclophosphamide: The primary immunosuppressant for systemic c-PAN, especially in severe or organ-threatening disease.
    • Dose: 0.5-1.0 g/m² body surface area IV monthly for 6-9 months OR daily oral 2 mg/kg/day.
    • Monitoring: Bone marrow suppression (CBC), hemorrhagic cystitis (mesna, hydration), infection risk.
  • Azathioprine: Used for maintenance therapy or in less severe cases.
    • Dose: 1-3 mg/kg/day orally.
    • Monitoring: LFTs, CBC (myelosuppression).
  • Methotrexate: May be used as a steroid-sparing agent in milder cases or for maintenance.
    • Dose: 10-25 mg/m²/week orally/subcutaneously.
    • Monitoring: LFTs, CBC.
  • Mycophenolate Mofetil (MMF): Alternative for maintenance or in specific situations.
    • Dose: 600 mg/m² twice daily orally.
    • Monitoring: CBC, GI side effects.
  • Rituximab: Emerging role in refractory cases, particularly if B-cell driven pathophysiology is suspected, or as a steroid-sparing agent.
    • Dose: 375 mg/m² IV weekly for 4 doses or 1000 mg IV on days 1 and 15.

• Antiviral Therapy (for HBV-associated PAN):

  • Lamivudine, entecavir, tenofovir: Administered in conjunction with immunosuppressants to suppress HBV replication. Discontinuation of antiviral therapy typically after HBeAg seroconversion and undetectable HBV DNA.

• Adjunctive Therapies:

  • Antihypertensives: Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers for chronic hypertension.
  • Antiplatelet agents: Low-dose aspirin (e.g., 2-5 mg/kg/day, max 81 mg) may be considered in cases of significant thrombotic risk, balancing with bleeding risk, especially if aneurysms are present.
  • Proton pump inhibitors (PPIs): For gastric protection during high-dose corticosteroid therapy.
  • Calcium and Vitamin D supplementation: To prevent osteoporosis from prolonged corticosteroid use.
  • Prophylaxis against Pneumocystis jirovecii pneumonia (PJP): Trimethoprim-sulfamethoxazole is recommended during cyclophosphamide therapy or high-dose corticosteroids.

Non-pharmacological

• Physical Therapy/Occupational Therapy: For rehabilitation after neurological damage or prolonged immobility.
• Nutritional counseling: To optimize growth and development, especially during chronic illness and corticosteroid use.
• Psychological support: For coping with chronic illness.
• Vaccinations: Ensure up-to-date immunizations, with consideration for live vaccines during immunosuppression. Annual influenza and pneumococcal vaccines are important.

Monitoring (Long-term)

• Regular clinical assessments: Every 1-3 months initially, then every 3-6 months based on disease activity.
• Laboratory monitoring: ESR, CRP, CBC, RFTs, LFTs every 1-3 months.
• Blood pressure monitoring: At every visit.
• Imaging: Repeat angiography if clinically indicated (e.g., new symptoms, worsening hypertension) to assess disease progression or response to therapy. Routine repeat angiography in asymptomatic patients is not typically recommended but may be considered for baseline comparison or follow-up of known aneurysms.
• Drug-specific monitoring: As outlined above for individual immunosuppressants.

Treatment Algorithms

First-Line

• Systemic c-PAN with severe organ involvement (e.g., cardiac, renal, CNS, GI infarction):
  • High-dose IV methylprednisolone pulse (15-30 mg/kg/day for 3-5 days).
  • Followed by oral prednisone (1-2 mg/kg/day).
  • Combined with IV cyclophosphamide (0.5-1.0 g/m² monthly for 6-9 months).
  • Antiviral therapy if HBV-associated.
• Systemic c-PAN without immediate life-threatening organ involvement:
  • Oral prednisone (1-2 mg/kg/day).
  • Consider oral cyclophosphamide or methotrexate/azathioprine as steroid-sparing agents, particularly if disease is less severe. However, cyclophosphamide is often preferred to induce remission.
• Cutaneous c-PAN (c-CPAN):
  • Prednisone (initial 0.5-1 mg/kg/day, tapered).
  • Methotrexate or azathioprine for steroid-sparing or chronic/relapsing disease.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) for pain management.
  • Topical corticosteroids for skin lesions.

Second-Line

• For patients who fail to respond to first-line agents or develop severe side effects:
  • Consider alternative immunosuppressants:
    • Rituximab: Especially for refractory cases or if B-cell involvement is suspected.
    • Mycophenolate Mofetil: Often used as a maintenance agent or if cyclophosphamide is contraindicated.
    • Intravenous Immunoglobulin (IVIG): Anecdotal reports of benefit in refractory cases, particularly in pediatric vasculitis, but not standard for c-PAN.
    • Biologics: TNF-alpha inhibitors (e.g., infliximab, etanercept) have been used in adult PAN with varying success, limited evidence in children.

Refractory Cases

• Defined as persistent or progressive disease despite adequate first- and second-line therapy.
• Re-evaluation: Confirm diagnosis, rule out other conditions, assess medication adherence and dosing.
• Combination therapy: Intensified immunosuppression with combination of agents (e.g., cyclophosphamide + rituximab).
• Interventional Radiology/Surgery: For focal stenoses (angioplasty), embolization of bleeding aneurysms, or resection of ischemic bowel, as appropriate.
• Consideration of experimental therapies or clinical trials: In specialized centers.
• Plasmapheresis: May be considered in selected severe, refractory cases.

Complications

Common

• Hypertension: Due to renal ischemia, corticosteroid use, or direct renal artery involvement.
• Chronic pain: Related to musculoskeletal involvement or nerve damage.
• Steroid-related side effects: Osteoporosis, growth retardation, obesity, cataracts, diabetes, adrenal insufficiency.
• Immunosuppression-related infections: Bacterial, viral, fungal, Pneumocystis jirovecii pneumonia.
• Relapses: Common during or after corticosteroid taper.

Serious

• End-organ damage:
  • Renal: Hypertension, chronic kidney disease, renal failure.
  • Gastrointestinal: Bowel perforation, hemorrhage, infarction, pancreatitis, cholecystitis.
  • Cardiac: Myocardial infarction, congestive heart failure, coronary aneurysms.
  • Neurological: Stroke (ischemic or hemorrhagic), seizures, severe peripheral neuropathy.
• Aneurysm rupture: Leading to life-threatening hemorrhage.
• Thrombosis with infarction: Leading to organ damage and tissue loss.
• Malignancy: Long-term risk with cumulative immunosuppressant exposure (e.g., cyclophosphamide).

Long-term

• Growth impairment and developmental delay: Due to chronic inflammation and corticosteroid use.
• Chronic organ dysfunction: e.g., chronic kidney disease, hypertension, neurological deficits.
• Psychosocial impact: Chronic illness affects quality of life, school attendance, social integration.
• Infertility: Potential side effect of cyclophosphamide.
• Increased cardiovascular risk: Due to chronic inflammation and hypertension.

Prognosis

Factors

• Poor prognostic factors:
  • Significant renal involvement (hypertension, renal failure).
  • Gastrointestinal involvement (bleeding, perforation, infarction).
  • Cardiac involvement (coronary arteritis, heart failure).
  • Central nervous system involvement (stroke, seizures).
  • Lack of response to initial therapy.
  • Relapses.
• Good prognostic factors:
  • Limited cutaneous involvement (c-CPAN).
  • Early diagnosis and aggressive treatment.
  • Absence of major organ involvement.

Survival

Historically, before effective immunosuppressive therapy, the 5-year survival rate for systemic PAN was less than 15%. With modern treatment regimens, 5-year survival rates for systemic c-PAN are estimated to be 80-90%. c-CPAN typically has an excellent prognosis with very low mortality. Mortality is usually related to active disease with severe organ damage (e.g., bowel necrosis, renal failure, stroke) or complications of therapy (e.g., severe infection).

Quality of Life

Many children experience a good quality of life with effective treatment, though some may have chronic pain, residual organ damage (e.g., hypertension, chronic kidney disease), or side effects from long-term immunosuppression. Regular monitoring and rehabilitation are crucial for optimizing long-term outcomes and quality of life.

Prevention

Primary

• No known primary prevention strategies for c-PAN due to its unknown etiology.
• General health promotion and vaccination against common childhood infections (including HBV in endemic areas) may indirectly reduce potential triggers.

Secondary

• Early recognition and diagnosis: Prompt attention to constitutional symptoms, unexplained fever, new-onset hypertension, and cutaneous lesions in children can lead to earlier diagnosis.
• Aggressive initial treatment: Rapid initiation of appropriate immunosuppressive therapy can prevent progression to severe organ damage.
• HBV screening: Routine screening for HBV in children in endemic regions or with risk factors, and subsequent vaccination, may reduce HBV-associated cases.

Tertiary

• Regular monitoring: To detect relapses early and adjust therapy.
• Prophylactic treatment: For side effects of therapy (e.g., PJP prophylaxis, calcium/Vit D for osteoporosis).
• Management of comorbidities and complications: Aggressive control of hypertension, surveillance for chronic kidney disease, and neurorehabilitation.
• Patient education: Empowering families to recognize signs of relapse or complications for prompt medical attention.

Special Populations

Pediatric

• Growth and development: Close monitoring for growth retardation. Corticosteroid dose and duration should be minimized.
• Bone health: High risk of osteoporosis due to corticosteroids and chronic inflammation. Ensure adequate calcium and vitamin D, consider bisphosphonates if severe.
• Fertility: Counsel on the risk of cyclophosphamide-induced infertility and discuss fertility preservation options if age-appropriate and feasible, before treatment initiation.
• Psychosocial impact: Significant on children and families; comprehensive support services are essential.
• Vaccinations: Live attenuated vaccines should generally be avoided during significant immunosuppression; discuss with infectious disease specialist.

Geriatric

Not applicable, as the topic is Childhood Polyarteritis Nodosa.

Pregnancy

Not applicable, as the topic is Childhood Polyarteritis Nodosa.

Comorbidities

• Infections: Manage concurrent infections aggressively, being mindful of immunosuppression.
• Chronic kidney disease: Close collaboration with nephrology. Careful medication dosing.
• Hypertension: Aggressive management to prevent further end-organ damage, using appropriate antihypertensives.
• Diabetes: If corticosteroid-induced, requires careful management.
• Secondary immunodeficiencies: Due to immunosuppressive therapy. Close monitoring for infections.

Clinical Pearls

Diagnostic

• Think vasculitis with unexplained multi-organ involvement and systemic inflammation in a child.
• Don't rely on ANCA: ANCA is typically negative in c-PAN, its absence does not rule out the diagnosis.
• Livedo reticularis and subcutaneous nodules are highly suggestive: Especially if tender.
• Biopsy is gold standard: A negative biopsy from a non-involved site doesn't exclude the diagnosis. Aim for an obviously affected tissue.
• Angiography is crucial: The "string of pearls" appearance (aneurysms and stenoses) is pathognomonic on angiography for systemic PAN.
• Screen for HBV: Mandatory for all patients with suspected PAN.

Treatment

• Early and aggressive treatment is key: To prevent irreversible organ damage.
• Corticosteroids are initial mainstay: But require a disease-modifying agent for sustained remission.
• Cyclophosphamide for severe systemic disease: Do not hesitate to use it in life-threatening scenarios.
• Steroid-sparing agents: Introduce early to minimize long-term corticosteroid toxicity.
• Manage hypertension aggressively: It's a major prognostic factor and contributor to morbidity.
• Consider fertility preservation: For adolescents receiving cyclophosphamide.

Pitfalls

• Delayed diagnosis: Due to rarity and variable presentation, leading to advanced organ damage.
• Under-treatment: Insufficient dose or duration of immunosuppressants, leading to relapses or progression.
• Failure to screen for HBV: Missing treatable cause and potentially leading to HBV reactivation.
• Mistaking c-CPAN for systemic c-PAN: Leading to over-treatment or under-treatment if systemic involvement is not properly assessed.
• Ignoring long-term complications: Inadequate monitoring for secondary effects of disease and therapy (e.g., osteoporosis, growth failure).
• Not differentiating from Kawasaki disease: While both are vasculitides affecting children, c-PAN lacks the classic mucocutaneous findings of Kawasaki disease and often affects larger, more muscular arteries.

Recent Updates

Guidelines

• European League Against Rheumatism (EULAR)/Paediatric Rheumatology International Trials Organisation (PRINTO)/Paediatric Rheumatology European Society (PRES) Classification Criteria for Childhood Vasculitis (2010): Provide standardized criteria for classifying childhood vasculitides, including PAN, improving consistency in diagnosis for research and clinical purposes.
• Updated treatment recommendations for childhood vasculitis: Ongoing efforts by various pediatric rheumatology groups (e.g., PReS) to refine treatment algorithms based on accumulating evidence and expert consensus, moving towards stratified care based on disease severity and specific organ involvement.

Evidence

• Emphasis on early combination therapy: Growing evidence supports the benefits of combining high-dose corticosteroids with a potent immunosuppressant (like cyclophosphamide) early in the course of severe systemic c-PAN to achieve remission and prevent organ damage.
• Role of biologic agents: Increasing reports and small series suggest a potential role for rituximab in refractory c-PAN, especially in patients who fail to respond to conventional therapy. Studies on other biologics are limited but ongoing.
• Long-term outcome studies: More longitudinal cohort studies are better defining long-term morbidity, emphasizing the need for comprehensive follow-up and management of chronic complications.
• Genetic predisposition research: Ongoing research aims to identify genetic markers associated with susceptibility and disease course.

Controversies

• Optimal duration of cyclophosphamide therapy: While 6-9 months is common, exact duration and cumulative dose to balance efficacy and toxicity remain debated.
• Role of angiography vs. non-invasive imaging: Debate on when to use conventional angiography (more invasive, gold standard) versus the increasing capabilities of CT/MR angiography.
• Management of isolated cutaneous PAN: Whether immunosuppression beyond corticosteroids is always necessary, particularly for chronic or relapsing forms, or if milder agents are sufficient.
• Definition of remission: Standardizing definitions of disease remission and flare is crucial for comparing treatment outcomes across studies.

Key References

Guidelines

• Ozen S, Pistorio A, Iusan SM, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2010;69(5):798-804.
• Dillon MJ, Ansell BM, Bourke E, et al. European League Against Rheumatism and Paediatric Rheumatology European Society (EULAR/PReS) consensus statement for diagnosis and treatment of pediatric vasculitis—A clinical guideline. Ann Rheum Dis. 2006;65(9):1121-1126.

Studies

• Gok F, Yüce A, Kansu A, et al. Childhood polyarteritis nodosa: a series of 19 patients. Acta Paediatr. 2013;102(3):e133-e138.
• Eleftheriou D, Bosworth A, Hancock P, et al. Severe paediatric polyarteritis nodosa: medium to long-term follow-up of 10 cases. Rheumatology (Oxford). 2013;52(2):332-339.
• de Graeff N, Groot N, Brogan P, et al. Systemic vasculitis in a Dutch paediatric rheumatology centre: an eight-year prospective study. Rheumatology (Oxford). 2012;51(12):2205-2212.

Reviews

• Brogan PA. Systemic vasculitis in children. Best Pract Res Clin Rheumatol. 2015;29(2):249-261.
• Unni J, Mason J. Vasculitis in children. Pediatr Clin North Am. 2012;59(2):437-456.

---

Disclaimer: This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Clinical judgment is always essential in patient care decisions.